Zylacta

Zylacta Corporation is a private biotechnology company headquartered in Gaithersburg, Maryland, focused on developing immunotherapy medicines derived from bacterial cell wall fragments. Established in 2004, the company utilizes its proprietary eDD™ technology platform to produce a diverse library of natural glycopeptides with broad therapeutic potential. Zylacta's research primarily targets viral diseases such as Hepatitis C, HIV, and Dengue, as well as mesodermal cancers and chronic liver diseases. The company's lead programs, including ZL016 for aplastic anemia, have progressed into early-stage clinical development. By leveraging the immunomodulatory properties of probiotic cell wall fragments, Zylacta aims to create a new class of drugs for apoptosis modulation and immune system stimulation.